Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire  Roos J.

Slides:



Advertisements
Similar presentations
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Survey on computer aided decision support for diagnosis of celiac disease Sebastian Hegenbart, Andreas Uhl, Andreas Vécsei Computers in Biology and Medicine.
Middle age self-report risk score predicts cognitive functioning and dementia in 20– 40 years  Eero Vuoksimaa, Juha O. Rinne, Noora Lindgren, Kauko Heikkilä,
Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment  Lies Clerx, Ineke A. van.
DIAGNOSTIC ACCURACY AND CONFIDENCE IN THE CLINICAL DETECTION OF COGNITIVE IMPAIRMENT IN EARLY-STAGE PARKINSON’S DISEASE  Kathryn A. Wyman-Chick, Phillip.
Volume 3, Issue 4, Pages (November 2017)
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study  Wesley.
Manuela Tondelli, Gordon K. Wilcock, Paolo Nichelli, Celeste A
Volume 3, Issue 1, Pages 1-9 (January 2017)
Different pathways to Alzheimer’s disease
Flora H. Duits, Niels D. Prins, Afina W. Lemstra, Yolande A. L
Copyright © 2000 American Medical Association. All rights reserved.
NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D. 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3, Pages (September 2017)
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample  Marie Eckerström,
Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease  Valérie.
The differential diagnosis of amnestic mild cognitive impairment and Alzheimer's disease dementia by hippocampal volume measurement with MR in a chinese.
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints  Argonde C. van Harten, Pieter Jelle Visser,
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design  Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.
Sietske A. M. Sikkes, Elly S. M. de Lange-de Klerk, Yolande A. L
Joana R. Guedes, Isabel Santana, Catarina Cunha, Diana Duro, Maria R
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease  Valentina Escott-Price, Maryam Shoai, Richard Pither, Julie.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Volume 3, Issue 2, Pages (June 2017)
Volume 5, Pages (December 2016)
Multidimensional assessment of challenging behaviors in advanced stages of dementia in nursing homes—The insideDEM framework  Stefan Teipel, Christina.
An amylin analog used as a challenge test for Alzheimer's disease
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission.
Colin Groot, Chris W. J. van der Weijden, Wiesje M
Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline  Sander C.J.
Volume 2, Issue 1, Pages (January 2016)
Volume 3, Issue 1, Pages (January 2017)
Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang 
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin  Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,
Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States.
Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)
Early Dementia Distinguishing AD From MCI
Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective
Identifying and validating biomarkers for Alzheimer's disease
Identifying and validating biomarkers for Alzheimer's disease
Martin R. Farlow, MD  Mayo Clinic Proceedings 
Fusion of deep learning models of MRI scans, Mini–Mental State Examination, and logical memory test enhances diagnosis of mild cognitive impairment  Shangran.
Yiqin Mong, MSc, Tilda W. Teo, MSc, Shamay S. Ng, PhD 
Steven D. Targum, Christopher J. Catania 
Biomarker Modeling of Alzheimer’s Disease
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Volume 17, Issue 2, Pages (February 2018)
The validity of the Memory Alteration Test and the Test Your Memory test for community- based identification of amnestic mild cognitive impairment  Seline.
NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D. 
Short-form activity measure for post-acute care 1
Evaluation of diagnostic tests
Error processing in patients with Alzheimer's disease
Isaline C. Eyssen, MSc, OT, Martijn P
Lynnette G. Kay, BOccThy, Anita C. Bundy, ScD, Lindy M. Clemson, PhD 
Clinical diagnosis of symptomatic midfoot osteoarthritis: cross-sectional findings from the Clinical Assessment Study of the Foot  M.J. Thomas, E. Roddy,
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective  Matthew Baumgart, Heather M. Snyder,
Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
Raban V. Jeger, MD, Peter Rickenbacher, MD, Matthias E
Massimo S. Fiandaca, Mark E. Mapstone, Amrita K. Cheema, Howard J
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS  Betty M. Tijms, Mara ten Kate, Sander C.J.
Different pathways to Alzheimer’s disease
Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years  Kevin A. Matthews,
NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D. 
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Presentation transcript:

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire  Roos J. Jutten, Carel F.W. Peeters, Sophie M.J. Leijdesdorff, Pieter Jelle Visser, Andrea B. Maier, Caroline B. Terwee, Philip Scheltens, Sietske A.M. Sikkes  Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring  Volume 8, Pages 26-35 (January 2017) DOI: 10.1016/j.dadm.2017.03.002 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Example item of the A-IADL-Q, including response options and scoring. Abbreviation: A-IADL-Q, Amsterdam IADL Questionnaire. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 8, 26-35DOI: (10.1016/j.dadm.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Flowchart of the item selection procedure that led to the short version of the Amsterdam IADL Questionnaire (A-IADL-Q). Abbreviations: IADL, Instrumental Activities of Daily Living; IRT, Item Response Theory. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 8, 26-35DOI: (10.1016/j.dadm.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Item information curves of the 30 Amsterdam IADL items that resulted in the short version. The bold black line represents the total test information curve. The latent trait ranges from −4 (good IADL functioning) to +4 (poor IADL functioning). Abbreviation: IADL, instrumental activities of daily living. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 8, 26-35DOI: (10.1016/j.dadm.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 4 Short version latent trait scores for each diagnostic group. Latent trait scores reflect IADL functioning, with higher scores indicating poorer IADL functioning. Post hoc analyses gave the following significant pairwise differences: (1) NC versus all other groups; (2) SCD versus AD dementia, non-AD dementia, and Other group; and (3) MCI versus AD dementia. Abbreviations: AD, Alzheimer's disease; IADL, instrumental activities of daily living; MCI, mild cognitive impairment; NC, normal cognition; SCD, subjective cognitive decline. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 8, 26-35DOI: (10.1016/j.dadm.2017.03.002) Copyright © 2017 The Authors Terms and Conditions